Introduction to Tirzepatide
As the world's first GIP/GLP-1 dual receptor agonist pharmaceutical raw material, it's crafted via advanced synthesis and purification, with ≥95% bioavail ability. Unlike single-target metabolic drugs, its core edge is dual-receptor co-activation, breaking single-target GLP-1 efficacy limits to synergize weight loss and blood glucose control, with longer-lasting results and lower blood glucose fluctuation risk.

Functional Introduction
As a dual GIP/GLP-1 receptor agonist, this product exerts core metabolic regulatory functions through synergistic receptor activation. It achieves simultaneous weight loss and blood glucose control, with obvious advantages over single-target drugs:
- Weight Loss Efficacy: Inhibits central appetite, delays gastric emptying, and accelerates fat oxidation, with durable effects that are not easy to rebound.
- Blood Glucose Regulation: Precisely responds to blood glucose changes, promotes insulin secretion, inhibits glucagon release, and stabilizes blood glucose levels.
- Safety & Convenience: Adverse reactions are mainly mild gastrointestinal discomfort, reversible and alleviable; only one subcutaneous injection per week, with adjustable dosage and high patient compliance.

Application Fields Introduction
- Medical Diagnosis & Treatment: Used for obese adults and type 2 diabetes with obesity globally. Recommended initial dose 10mg/week, adjustable, improving patient compliance.
- Scientific Research & Experiment: Ideal for metabolic disease research and new formulation development. Customizable purity up to 99.8%, small-volume packaging for refined experiments.
- OEM/ODM Services: Supports production of injection regulators. Offers 5-50mg/vial customization and multi-language labels, helping brands enter global markets quickly.

Professional Specification Parameters
|
Module Category |
Test Item |
Specification Standard |
Test Method |
|
Core Quality |
Purity / Bioavailability |
≥99.5% / ≥95% |
HPLC |
|
Safety&Compliance |
Heavy Metals / Microorganisms |
≤10ppm / ≤100 CFU/g (Negative) |
Atomic Absorption Spectrometry |
|
Production Adaptability |
Solubility / Particle Size |
≥30mg/mL (aqueous phase) / 95% passing 80 mesh sieve |
Sieving Method |
|
Stability |
Loss on Drying / Activity Retention Rate |
≤0.5% / ≥90% (48 hours at 2-15℃) |
High-Temperature Ignition Method / HPLC Tracking Method |
Why Choose Our Tirzepatide?
- Dual-Target Technology Barrier: Exclusively optimizes the dual receptor activation ratio, ensuring 15% higher efficacy than ordinary raw materials, with patented purification technology.
- Risk-Free Trial & Flexible Supply: Provides 5 free samples (delivery in 3-7 days) with a low MOQ of 10 boxes. Supports customization of 5-50mg/vial specifications to avoid inventory backlogs.
- Global Compliance Assurance: Offers a full set of compliant documents (COA/GMP Certificate/SDS), meeting EU, US and Chinese standards. A dedicated team assists with regional customs clearance, ensuring zero compliance risks.
- Cost-Effective Factory Direct Supply: Saving 8%-12% of costs compared to traders, with excellent batch-to-batch purity stability.
- One-Stop Value-Added Services: 12-hour professional response, one-on-one injection formulation guidance, and unconditional return for quality issues to accelerate your product launch.
Contact Us & Exclusive Benefits
Free samples + professional dosage guidance + instant quotation! Contact us now to seize the multi-billion-dollar GLP-1 market opportunity.
|
|
|
|
Overseas Contact |
Skype/WhatsApp: +8617691140832 |
Notes
- For research/medical/OEM use only. Not for direct human consumption or clinical treatment. Regional dosage standards must be followed.
- Avoid contact with strong oxidants. Store in a sealed, cool, dry and light-proof environment. Use within 7 days after opening.
- Strictly prohibited for prohibited areas (e.g., illegal weight loss products). We are not liable for disputes arising from improper use.
Hot Tags: tirzepatide 10mg 30mg, China tirzepatide 10mg 30mg manufacturers, suppliers, factory
